InSite Vision Establishes Scientific Advisory Board

InSite Vision Incorporated (OTCBB:INSV) today announced the appointment of a new Scientific Advisory Board (SAB) to help guide and shape its research programs in the development of novel ophthalmic medicines. Members of InSite’s SAB represent leaders in ophthalmic research, treatment and clinical drug development, including Richard Lindstrom, M.D., Gary Foulks, M.D., Michael Lemp, M.D., and Kelly Nichols, O.D., M.P.H., Ph.D. The SAB will be led by InSite’s Chief Medical Officer, Kamran Hosseini, M.D., Ph.D. and Brian Levy, O.D., a member of InSite’s Board of Directors, will also participate in all SAB meetings.

"We are very pleased to bring together these key eye care thought leaders to establish the InSite Vision Scientific Advisory Board. Their deep insight into the etiology of important ocular diseases will be instrumental in advancing our therapeutic programs,” said Dr. Hosseini. "The interest and direct participation of these world-class medical professionals on our SAB reflects the progress InSite is achieving in the development of ocular medicines. Our SAB members have already made significant contributions to our current clinical development programs, providing input on trial protocols and endpoint design. We look forward to future contributions in the same vein.”

Richard Lindstrom, M.D., founder and attending surgeon of the Minnesota Eye Consultants and Adjunct Professor Emeritus at the University of Minnesota Department of Ophthalmology, is a board certified ophthalmologist and internationally recognized leader in ocular surgery. He has been at the forefront of ophthalmology’s evolutionary changes throughout his career as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon. He is Chief Medical Editor of the USA and International editions of Ocular Surgery News. Dr. Lindstrom is past President of the American Society of Cataract and Refractive Surgeons (ASCRS). He serves on the ASCRS Executive Committee and is the Chair of the ASCRS Foundation. Dr. Lindstrom is also past President of the International Society of Refractive Surgery, the International Intraocular Implant Club, and the International Refractive Surgery Club. He is also the Global Education Liaison of the International Society of Refractive Surgery of the American Academy of Ophthalmology. Prior to joining the SAB, Dr. Lindstrom provided valuable guidance to InSite Vision on the protocol for the Phase 3 DOUBle clinical study for AzaSite Plus™ (ISV-502) and DexaSite™ (ISV-305).

Gary Foulks, M.D., is Emeritus Professor of Ophthalmology at the University of Louisville School of Medicine Department of Ophthalmology and Visual Sciences and is former Assistant Dean for Clinical Trial Research at the University of Louisville School of Medicine. Dr. Foulks has authored more than a hundred publications regarding his research in a wide variety of ophthalmologic areas and he is currently active in clinical trial research in ocular surface disease, dry eye and contact lens wear. Dr. Foulks presently is Editor-in-Chief of The Ocular Surface and is on the editorial boards of Cornea and the Eye and Contact Lenses (formerly the CLAO Journal). Before becoming an SAB member, Dr. Foulks consulted with InSite Vision on the DOUBle study protocol, as well as on the trial design for the company’s Phase 1/2 clinical trial of ISV-101 for the treatment of dry eye.

Michael Lemp, M.D., is a corneal specialist with a major research focus in dry eye and ocular surface disease where his work stands as the worldwide standard for the design of clinical trials for dry eye. He has served as Professor and Chairman of the Department of Ophthalmology at Georgetown University, as an officer and board member of many national and international ophthalmic organizations, member of the Food and Drug Administration (FDA) Ophthalmic Devices Advisory Board, and National Institutes of Health (NIH) Study Sections and advisory committees. Dr. Lemp has authored over 200 scientific articles and five books, and has served on national, international and government advisory boards. He is the Founding Editor-in-Chief of The Ocular Surface. He is currently Clinical Professor of Ophthalmology at Georgetown and George Washington Universities and is the Chief Medical Officer of Tearlab Inc.

Kelly Nichols, O.D., M.P.H., Ph.D., is a Professor at the University of Houston College of Optometry where she currently has an NIH grant to study dry eye in postmenopausal women. Dr. Nichols received a Doctor of Optometry degree from U.C. Berkeley and an M.P.H. and Ph.D. from Ohio State University. She serves as a medical advisor to the Sjogren’s Syndrome Foundation and sits on the governing board of the Tear Film and Ocular Surface Society and the Ocular Surface Society of Optometry. She participates as a reviewer for NIH Study Sections and is a member of several prominent ophthalmic journal editorial boards. Dr. Nichols has served as principal investigator or participated in numerous industry-sponsored studies in dry eye and Meibomian Gland Dysfunction (MGD), and recently served as the chair of the International Workshop on MGD. Dr. Nichols lectures and writes on dry eye, contact lenses, diabetes and public health, and women’s health issues.

Dr. Brian Levy, O.D., joined the Board of Directors with more than thirty years of industry experience. He is currently the Chief Scientific Officer of Nexis Vision, which is developing a novel refractive surgery technology. Among his many accomplishments, he oversaw the development of Besivance^®, an InSite Vision-licensed drug, while serving as a Corporate Vice President and Chief Medical Officer of Bausch & Lomb.

About InSite Vision

InSite Vision is advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite^® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite^® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance^® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch & Lomb and their partner Pfizer Inc. InSite Vision’s clinical-stage ophthalmic product pipeline includes AzaSite Plus™ (ISV-502) and DexaSite™ (ISV-305) for the treatment of eye infections, BromSite™ (ISV-303) for pain and swelling associated with ocular surgery, and ISV-101 for the treatment of dry eye disease. For further information on InSite Vision, please visit www.insitevision.com.